New combo pill aims to crush stubborn high cholesterol

NCT ID NCT04669041

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tested whether a single pill combining ezetimibe and rosuvastatin works better than rosuvastatin alone for lowering LDL (bad) cholesterol. The study included 305 Chinese adults whose cholesterol was not well controlled on statin therapy. Participants took either the combo pill or rosuvastatin for 8 weeks to compare LDL reduction and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ezetimibe and rosuvastatin combination pill
What this could lead to: If it works, this could offer a more effective once-daily pill to help people with high cholesterol reach their LDL goals without taking multiple medications.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The combination may cause more side effects than rosuvastatin alone, and benefits may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

Investigational Site Number :1560001

Beijing, 100029, China
Investigational Site Number :1560002

Tianjin, 300121, China
Investigational Site Number :1560003

Xuzhou, 221002, China
Investigational Site Number :1560005

Zhanjiang, 524001, China
Investigational Site Number :1560006

Hohhot, 010017, China
Investigational Site Number :1560007

Hohhot, 010050, China
Investigational Site Number :1560009

Wuhan, 430033, China
Investigational Site Number :1560010

Siping, 136000, China
Investigational Site Number :1560011

Zhenjiang, 212001, China
Investigational Site Number :1560014

Jilin City, 132011, China
Investigational Site Number :1560015

Dalian, 116033, China
Investigational Site Number :1560019

Yueyang, 414000, China
Investigational Site Number :1560020

Jinan, 250013, China
Investigational Site Number :1560021

Beijing, 101200, China
Investigational Site Number :1560022

Xi'an, 710061, China
Investigational Site Number :1560025

Bengbu, China
Investigational Site Number :1560027

Shanghai, 200120, China
Investigational Site Number :1560029

Haikou, 570311, China
Investigational Site Number :1560033

Baotou, 014010, China
Investigational Site Number :1560034

Shenyang, 110016, China
Investigational Site Number :1560035

Wuhan, 430080, China
Investigational Site Number :1560037

Zibo, 255036, China
Investigational Site Number :1560041

Chengdu, 610041, China
Investigational Site Number :1560045

Changchun, 130021, China
Investigational Site Number :1560047

Wuhan, 430022, China
Investigational Site Number :1560052

Changsha, 410013, China
Investigational Site Number :1560053

Tianjin, 300140, China
Investigational Site Number :1560055

Nanning, 530031, China
Investigational Site Number :1560057

Yanji, 133000, China
Investigational Site Number :1560060

Chongqing, 400013, China
Investigational Site Number :1560061

Lishui, 323000, China
Investigational Site Number :1560062

Yuncheng, 044000, China
Investigational Site Number :1560063

Zhuzhou, 412007, China
Investigational Site Number :1560064

Yinchuan, 750004, China
Investigational Site Number :1560065

Yangzhou, 225001, China
Investigational Site Number :1560066

Nanjing, 210011, China
Investigational Site Number :1560067

Changchun, 130033, China
Investigational Site Number :1560068

Beijing, 100050, China
Investigational Site Number :1560070

Xi'an, 710068, China
Investigational Site Number :1560071

Liuzhou, 545006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.